We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Implementation of License of Aureus Pharma’s Knowledge Databases by GSK

Read time: Less than a minute

Aureus Pharma has announced that GlaxoSmithKline (GSK) has signed a multi-year license for Aureus Pharma’s AurSCOPE Knowledge databases. 

Researchers at GSK’s global research and development centers will gain access to Aureus’ Knowledge databases including AurSCOPE GPCR, Ion Channel, hERG, and ADME/Drug-Drug Interactions.

In addition, GSK has licensed the recently released AurSCOPE Kinase product making it the first customer of this knowledge base which is of major importance for oncology and other diseases.

"AurSCOPE knowledge databases are comprised of detailed quantitative biological and chemical data," said Dr. Andre Michel, CEO of Aureus Pharma.

"With its unrivalled level of quality, Aureus Pharma’s knowledge driven discovery platform provides drug discovery teams with comprehensive information to accelerate both the drug discovery and development process."

"We are pleased that GSK has selected Aureus Pharma as their global solution provider of integrated knowledge databases."

The addition of a pharmaceutical R&D world leader, such as GSK, to Aureus’ growing list of customers is further confirmation that AurSCOPE is becoming accepted as the knowledge base of choice for pharmaceutical and biotechnology organizations.